机构:[1]Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, China[2]Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, China[3]Joint Laboratory of Reproductive Medicine, Key Laboratory of Birth Defects and Related Diseases of Women and Children, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, China[4]Department of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Cancer Hospital A.liate to School of Medicine, Chengdu, Sichuan 610041, China四川省肿瘤医院
第一作者机构:[1]Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, China[2]Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, China
通讯作者:
通讯机构:[1]Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, China[2]Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, China
推荐引用方式(GB/T 7714):
Sun Shu-Wen,Chen Yan,Liao Hui-Juan,et al.LINC00461 Regulates the Recurrence of Large B Cell Lymphoma through the miR-411-5p/BNIP3 Pathway[J].EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE.2022,2022:doi:10.1155/2022/9100056.
APA:
Sun Shu-Wen,Chen Yan,Liao Hui-Juan,Zhang Wei,Xu Wen-Ming&He Guo-Qian.(2022).LINC00461 Regulates the Recurrence of Large B Cell Lymphoma through the miR-411-5p/BNIP3 Pathway.EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE,2022,
MLA:
Sun Shu-Wen,et al."LINC00461 Regulates the Recurrence of Large B Cell Lymphoma through the miR-411-5p/BNIP3 Pathway".EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2022.(2022)